Concord Biotech gets USFDA EIR for Limbasi facility

Published On 2023-08-23 10:00 GMT   |   Update On 2023-08-23 10:00 GMT
Advertisement

AhmedabadThrough a recent BSE filing, Concord Biotech Limited has notified that the Company has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) indicating closure of inspection and classifying the Limbasi (Unit III) facility as "no action indicated" ("NAI").

NAI means no objectionable conditions or practices were found during the inspection (or the objectionable conditions found do not justify further regulatory action).

Advertisement

USFDA inspected the Company’s Manufacturing Unit III, Plot No. 84 And 668, Ranasar and Malawada, Limbasi Sojitra Road, Near Limbasi, Taluka- Matar, Kheda, Gujarat from Monday, 26th June, 2023 to Friday 30th June, 2023.

"Based on this inspection and the USFDA NAI classification, this facility is in compliance with regard to current good manufacturing practices (cGMP)," the Company stated.

Read also: Concord Biotech up 33 percent in debut, nets over USD 1 billion in valuation

Concord Biotech Limited is a R&D driven biopharma Company that manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. Concord, founded in the 2000, has transformed from a single-product company to a broad-spectrum solution provider, offering products across diversified therapeutic segments. Concord has a presence in more than 70 countries worldwide with efficient distribution infrastructure in markets like the USA, Europe, Japan, Latin America, Africa, Asia, besides significant presence in Indian market. The Company has two API manufacturing units and one finished formulation unit, all located near Ahmedabad, Gujarat, India

Read also: Concord Biotech files IPO papers with SEBI

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News